SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
VVOS reported three and nine months ended September 30, 2026 results. The price and volatility reaction is pending.
VVOSearnings

Earnings reactions

Vivos Therapeutics, Inc. (VVOS) FY2026 earnings

November 17, 2026 · SharpeIQ Research Desk

Reported results

  • Total revenue was $6.4 million for the third quarter of 2026, compared to $6.8 million for the third quarter of 2025.
  • Gross profit was $3.3 million for the third quarter of 2026, compared to $3.9 million for the third quarter of 2025.
  • Gross margin was 52% in the third quarter of 2026 compared to 58% in the third quarter of 2025.
  • Total operating expenses for the third quarter ended September 30, 2026 were $7.2 million, compared to $8.7 million in the same period a year ago.
  • Operating loss was $3.9 million for the third quarter of 2026, compared to $4.7 million in the third quarter of 2025.
  • Net loss for the third quarter of 2026 was $2.0 million, compared to $5.4 million in the third quarter of 2025.

Notes

Net loss for the third quarter of 2026 included approximately $2.9 million of other income from the reversal of a previously recorded Employee Retention Credit liability.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-17 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →